ID.1
Item
age over 18 years
boolean
C0001779 (UMLS CUI [1])
ID.2
Item
synovial swelling of at least 1 joint confirmed by clinical assessment
boolean
C0221608 (UMLS CUI [1])
ID.3
Item
duration of symptoms attributable to inflammatory joint disease (pain, swelling or early morning stiffness of >1 hour) of < 12 weeks.
boolean
C0436359 (UMLS CUI [1,1])
C0683381 (UMLS CUI [1,2])
ID.4
Item
seropositivity for rf and anti-ccp ab
boolean
C0035448 (UMLS CUI [1,1])
C1138802 (UMLS CUI [1,2])
ID.5
Item
women of childbearing potential or men capable of fathering children must be using adequate birth control measures (eg, abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilization) during the study.
boolean
C0009862 (UMLS CUI [1])
ID.6
Item
female subjects of childbearing potential must test negative for pregnancy
boolean
C0032961 (UMLS CUI [1])
ID.7
Item
previous history of inflammatory arthritis.
boolean
C0003864 (UMLS CUI [1])
ID.8
Item
previous use of dmards or anti-tnf-agents.
boolean
C0242708 (UMLS CUI [1,1])
C0281481 (UMLS CUI [1,2])
ID.9
Item
any current inflammatory condition with signs or symptoms that might confound the diagnosis (e.g. connective tissue disorders).
boolean
C0021368 (UMLS CUI [1])
ID.10
Item
clinical evidence of latent or active granulomatous infection, including tb, histoplasmosis, or coccidioidomycosis, prior to study entry.
boolean
C1610637 (UMLS CUI [1])
ID.11
Item
administration, or expected administration, of any live virus or bacterial vaccination within 3 months before the first administration of study agent, or during the trial.
boolean
C0042211 (UMLS CUI [1])
ID.12
Item
a history of an infected joint prosthesis, or administration of antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced.
boolean
C0410808 (UMLS CUI [1,1])
C0003232 (UMLS CUI [1,2])
ID.13
Item
known infection with hiv, hepatitis b, or hepatitis c.
boolean
C0019682 (UMLS CUI [1,1])
C0019163 (UMLS CUI [1,2])
C0019196 (UMLS CUI [1,3])
ID.14
Item
a serious infection that in the opinion of the investigator precludes receipt of a tnf blocking agent.
boolean
C3714514 (UMLS CUI [1])
ID.15
Item
serious and uncontrolled co-existing disease that in the opinion of the investigator preclude the use of tnf-blocking medication, methotrexate or depomedrone (including pulmonary disease on chest radiograph, congestive cardiac failure (nyha grade 3 or 4), history of demyelinating disease such as multiple sclerosis or optic neuritis).
boolean
C0012634 (UMLS CUI [1])
ID.16
Item
bleeding disorder of the use of anti-coagulants
boolean
C0003280 (UMLS CUI [1,1])
C0005779 (UMLS CUI [1,2])
ID.17
Item
any known malignancy or a history of malignancy within the previous 5 years (with the exception of a basal cell carcinoma that has been treated with no evidence of recurrence).
boolean
C0006826 (UMLS CUI [1])
ID.18
Item
any other contraindication to etanercept, methotrexate or parenteral depomedrone.
boolean
C0522473 (UMLS CUI [1,1])
C0717758 (UMLS CUI [1,2])
ID.19
Item
patients will also be excluded with the following laboratory results: haemoglobin <8.5 gm/dl, total white cell count <3.5 x 109/litre, serum transaminase value more than twice the upper limit of normal, and serum creatinine >150 micromoles/litre.
boolean
C0201899 (UMLS CUI [1,1])
C0518015 (UMLS CUI [1,2])
C0427547 (UMLS CUI [1,3])
C0600061 (UMLS CUI [1,4])